이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Functional Outcome of Organ Preservation After Neo-adjuvant Chemo Radiation for Rectal Cancer

2019년 9월 17일 업데이트: Maastricht University Medical Center

Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer

The primary objective is to describe the functional outcome of patients that choose for organ saving treatment.

연구 개요

상세 설명

Rectal cancer is a common form of cancer. Standard treatment for locally advanced rectal cancer is a long course of neoadjuvant radiation combined with chemotherapy (CRT) followed by resection. However, neoadjuvant CRT induces downsizing and downstaging, resulting in a complete response in 15-20% of the patients. In these patients surgery may be omitted. In the investigators previous study the investigators obtained good results with an organ saving treatment. Although the mortality and morbidity associated with radical surgery is avoided, the irradiated rectum remains in situ, possibly causing functional problems.

The primary objective is to describe the functional outcome of patients that choose for organ saving treatment. Functional outcome will be evaluated with questionnaires (quality of life) and manometric measurements (maximal resting pressure, maximal squeezing pressure, sphincter length, percentage asymmetry of the resting sphincter, sustained duration, length of the high pressure zone, rectoanal inhibitory reflex, rectal sensory threshold, and rectal compliance).

Secondary objectives include: the estimation of the cumulative risk of local failure within 5 years, the estimation of the cumulative risk of disease-free, distant-metastasis-free and overall survival within 5 years, determine the percentage of patients that chooses organ saving treatment instead of standard resection, determine the compliance to intensive follow-up, and compare the cost-effectiveness of organ saving treatment to standard surgical resection over a period of 5 years. These objectives will be assessed by frequent revision of the electronic patient file, as the patient is followed up to four times per year.

Study design: prospective observational registration study with 'invasive diagnostic procedures' Study population: The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).

Main study parameters/endpoints: The main study endpoint is the functional outcome scores based on questionnaires and manometric measurements Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The questionnaires take approximately 20 minutes to complete. There is a relatively low rate of side effects associated with manometric measurements. Results of this study will contribute to better understanding of functional complaints after rectal cancer treatment.

연구 유형

관찰

등록 (예상)

100

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0). Patients will be recruited from the outpatient clinic, by researchers or research nurses at Maastricht University Medical Center.

설명

Inclusion Criteria:

  • 18 years old
  • Patients with primary rectal cancer without distant metastases who underwent CRT and show clinical complete response or very good response :

    • Clinical complete response (ycT0N0) after neo-adjuvant chemoradiation will be determined clinically (digital rectal examination, endoscopy) and radiologically (contrast-enhanced-MRI)
    • Very good response (ycT1-2N0) after neo-adjuvant chemoradiation will be determined clinically (digital rectal examination, endoscopy) and radiologically (contrast-enhanced-MRI). These patients will undergo a TEM to resect the small residual tumor
  • Comprehension of the alternative strategies and the concept of unknown risks are clear to the patient
  • Choosing for the organ-saving treatment option (wait&see policy or TEM)
  • Informed consent

Exclusion Criteria:

  • Unable to understand or read Dutch
  • Unwilling to comply to the questionnaires or manometric measurement.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Study group
The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
  1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
  2. Short Form (36) health survey
  3. EORTC CR38
  4. Vaizey score
  5. Low Anterior Resection Syndrome (LARS) score
  6. International Index of Erectile Function for men
  7. International Prostate Symptom Score for men
  8. Female Sexual Function Index for women
Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Functional outcome
기간: 5 years

Functional outcome scores of patients that are treated with an organ saving strategy compared to patients who undergo the standard resection as described in literature.

Functional outcome will be evaluated with the following questionnaires:

  1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
  2. Short Form (36) health survey
  3. EORTC CR38
  4. Vaizey score
  5. Low Anterior Resection Syndrome (LARS) score
  6. International Index of Erectile Function for men
  7. International Prostate Symptom Score for men
  8. Female Sexual Function Index for women

Functional outcome will be measured by manometric measurements:

  1. mean basal pressure (mmH2O)
  2. maximum squeeze pressure (mmH2O)
  3. first sensation (mL)
  4. first urge to defecate (mL)
  5. maximum tolerable volume (mL)
5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Cumulative risk of local failure
기간: 5 years
All patients with a local recurrence will be excluded form further follow-up. This information will be based on an MRI of the lower abdomen in combination with endoscopy.
5 years
Cumulative risks of disease-free, distant-metastasis free and overall survival
기간: 5 years
5 years
The percentage of patients that choose the alternative strategies instead of traditional strategies and the motivation for their choice
기간: 3 years
3 years
The compliance to the intensive follow-up schedule
기간: 5 years
All patients are intended to participate in the standard follow-up schedule. Some of them may drop out due to other illness, ageing or other reasons. These patients will be included in the analysis as far as they participated.
5 years
Early detection of local failure (standard surgery still possible)
기간: 5 years
In the first year, every three months an MRI of the lower abdomen is made in combination with an endoscopy. From the second to the fifth year, these investigations will be done twice a year. With these short intervals, it is know that local recurence is detected in an early fase.
5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Geerard L Beets, MD, PhD, Surgery, MUMC+
  • 연구 의자: Rianne CJ Beckers, MD, MSc, Surgery/Radiology MUMC+
  • 연구 의자: Miriam M van Heeswijk, MD, MSc, Surgery/Radiology MUMC+
  • 연구 의자: Monique Maas, MD, PhD, Radiology, MUMC+

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2014년 3월 1일

기본 완료 (실제)

2017년 10월 1일

연구 완료 (예상)

2022년 9월 1일

연구 등록 날짜

최초 제출

2014년 10월 6일

QC 기준을 충족하는 최초 제출

2014년 10월 28일

처음 게시됨 (추정)

2014년 10월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2019년 9월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2019년 9월 17일

마지막으로 확인됨

2019년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다